The role of biomarkers and efficacy of roflumilast in the treatment of severe COPD
Kseniia Ostrovska, Iryna Savelikhina and Mykola Ostrovskyy
Our understanding of chronic obstructive pulmonary disease (COPD) has changed over the past two decades. It is the most common inflammatory disease of the airways, and the incidence of it is increasing throughout the world. Roflumilast - a phosphodiesterase-4 (PDE4) inhibitor, through selective inhibition of the PDE-4 enzyme prevents the breakdown of cyclic AMP, which plays an important role in regulating inflammatory cell activity. Most of the clinical features of COPD are determined by cytokines, which play a key role in the chronic inflammation. This study assessed the anti-inflammatory efficacy of roflumilast, in patients with stable severe COPD.
How to cite this article:
Kseniia Ostrovska, Iryna Savelikhina, Mykola Ostrovskyy. The role of biomarkers and efficacy of roflumilast in the treatment of severe COPD. Pharma Innovation 2018;7(3):512-514.